Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/28536
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Detailleur S. | en |
dc.contributor.author | Segelov E. | en |
dc.contributor.author | Re M.D. | en |
dc.contributor.author | Prenen H. | en |
dc.date.accessioned | 2021-05-14T09:36:39Z | en |
dc.date.available | 2021-05-14T09:36:39Z | en |
dc.date.copyright | 2021 | en |
dc.date.created | 20210128 | en |
dc.date.issued | 2021-01-28 | en |
dc.identifier.citation | Annals of Gastroenterology. 34 (1) (pp 68-72), 2021. Date of Publication: 2021. | en |
dc.identifier.issn | 1108-7471 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/28536 | en |
dc.description.abstract | Background 5-Fluorouracil (5-FU) is an agent frequently used in the treatment of solid cancers. A deficiency in the enzyme that catabolizes 5-FU leads to severe toxicity. The gene responsible for this enzyme is DPYD, located on chromosome 1q22. The most prevalent alteration described is DPYD*2A, which leads to a splicing defect and thus skipping of the translation of an entire exon. The objectives of this retrospective study were to describe the frequencies of DPYD gene mutations in a Belgian population and to correlate them with the grade of toxicity. Methods This was a retrospective, single-center study conducted at the University Hospitals Leuven, by reviewing a database of patients screened for DPYD gene mutations between May 2009 and June 2015 after prolonged grade 3-4 toxicity. Polymerase chain reaction sequencing of exons 2, 6, 10, 11, 13, 18, 19 and 22, and pyrosequencing of exon 14 were performed by an in-house laboratory. Results Of the 80 patients screened, 65 were heterozygous or compound heterozygous for DPYD and 3 had a homozygous mutation. The most prevalent mutation in our population was DPYD*9A. Conclusions Despite previous reports, in our small retrospective study the most prevalent variation in patients with severe adverse events was DPYD*9A. As this variant has previously been reported to be benign, we suggest that screening for dihydropyrimidine dehydrogenase deficiency should be extended across multiple exons of the DPYD gene.Copyright © 2021 Hellenic Society of Gastroenterology. | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | Hellenic Society of Gastroenterology | en |
dc.relation.ispartof | Annals of Gastroenterology | en |
dc.title | Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: A retrospective single-center study. | en |
dc.type | Article | en |
dc.identifier.affiliation | Oncology | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url= | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.20524/aog.2020.0551 | en |
dc.publisher.place | Greece | en |
dc.identifier.source | 2005832985 | en |
dc.identifier.institution | (Detailleur) Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium (Segelov) Department of Oncology, Monash University and Monash Health, Melbourne, VIC, Australia (Re) Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy (Prenen) Department of Oncology, University Hospital Antwerp, Edegem, Belgium | en |
dc.description.address | H. Prenen, University Hospital Antwerp, Department of Oncology, Wilrijkstraat 10, Edegem B-2650, Belgium. E-mail: hans.prenen@uza.be | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2021 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | 5-fluorouracil Deficiency Dihydropyrimidine dehydrogenase Toxicity | en |
dc.identifier.authoremail | Prenen H.; hans.prenen@uza.be | en |
dc.identifier.affiliationext | (Detailleur) Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium | - |
dc.identifier.affiliationext | (Re) Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy | - |
dc.identifier.affiliationext | (Prenen) Department of Oncology, University Hospital Antwerp, Edegem, Belgium | - |
dc.identifier.affiliationmh | (Segelov) Department of Oncology, Monash University and Monash Health, Melbourne, VIC, Australia | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairetype | Article | - |
crisitem.author.dept | Oncology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.